Sign in

Recursion

@recursionpharma.bsky.social
923 followers 6 following 207 posts

Decoding biology to radically improve lives. The industrial revolution of drug discovery is here. Learn more at recursion.com #techbio

PostsRepliesMedia
Recursion @recursionpharma.bsky.social · 27/07/2026
Hoifung Poon, PhD, formerly General Manager of Microsoft Research, has joined Recursion as the company’s first Chief AI Officer. In 15+ years at Microsoft, he led pioneering work in biomedical AI, multimodal foundation models & causal machine learning – including PubMedBERT, GigaPath & GigaTIME.
131
Recursion @recursionpharma.bsky.social · 15/07/2026
We’re headed to the U.S. Science Summit! On July 21, Recursion CEO Najat Khan, PhD, will join @biotechtv.bsky.social's inaugural U.S. Science Summit in Kendall Square for a fireside chat, “Who Will Shape the Future of Medicine?” www.biotechtv.com/us-science-s... #USsciencesummit #biotech #Boston
021
Recursion @recursionpharma.bsky.social · 24/06/2026
🤖 Automated labs will be a driving force in the AI drug discovery era. A new story in @sciam.bsky.social looks at how automated labs are adding new speed & efficiency to drug discovery & how Recursion is bringing “industrial scale” to lab automation. www.scientificamerican.com/article/auto...
011
Recursion @recursionpharma.bsky.social · 15/06/2026
🎉 We’re on the Shatter List! Recursion has been named to the 2026 Women Tech Council’s Shatter List. This is our 9th year making the list, which recognizes workplaces where talented people want to grow, lead, and build meaningful careers. 👉 Learn more: www.womentechcouncil.com/shatter-list/
011
Recursion @recursionpharma.bsky.social · 08/05/2026
Bigger isn't always better.” — Dave Hallett, CSO, Recursion At the @synbiobeta.bsky.social event, Dave joined fellow industry leaders to discuss "Solving the Scale Mismatch Between Cells and Patients in Virtual Biology." How do we better translate cellular insights to patient outcomes using AI?
020
Recursion @recursionpharma.bsky.social · 30/04/2026
Recursion will provide business updates and report our first quarter 2026 financial results on Wednesday, May 6, 2026, with an Earnings Call at 8:00 am ET / 6:00 am MT / 1:00 pm BST broadcast on our X, LinkedIn, and YouTube accounts. 👉Learn more: ir.recursion.com/news-release...
010
Recursion @recursionpharma.bsky.social · 10/03/2026
Recursion welcomed rare disease advocates, physicians, patients, and community members for “An Evening of Hope” last week in SLC. The event highlighted the critical work happening to raise awareness & accelerate new treatments & best support patients and their families who are waiting for a cure.
010
Recursion @recursionpharma.bsky.social · 24/02/2026
Recursion announced yesterday that the company will participate in a number of upcoming investor conferences. 👉 Check out the webcasts at ir.recursion.com. #investor #financial #AI #drugdiscovery #TechBio
010
Recursion @recursionpharma.bsky.social · 20/02/2026
Recursion CSO Dave Hallett was recently appointed as an AI Champion by the UK government. He’s one of 8 AI Champions and will be representing the life sciences industry, helping to inform, guide, and accelerate AI adoption plans in that space. 👉 Learn more: delivery.ai.gov.uk/48/ #TechBio #AI #UK
000
Recursion @recursionpharma.bsky.social · 28/01/2026
See you at #SLAS2026! Two of our AI drug discovery experts are presenting at the SLAS International Conference & Exhibition Feb. 7-11 in Boston - on Industrializing Drug Discovery with ML and Leveraging AI to Map Cellular Morphology Across Imaging Modalities. www.slas.org/events-calen...
000
Recursion @recursionpharma.bsky.social · 09/01/2026
Leveraging AI & real-world patient data to accelerate drug discovery. In a recent webinar, Sid Jain and Hayley Donnella of Recursion spoke to Shane Woods at Tempus AI about how patient data is driving the latest advances in AI drug discovery. www.tempus.com/resources/co... #TechBio #data 🧪
000
Recursion @recursionpharma.bsky.social · 04/12/2025
🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological & chemical datasets, AI models & one of the industry’s most powerful supercomputers. Learn about our progress & what's next: www.recursion.com/news/since-i... #virtualcell
030
Recursion @recursionpharma.bsky.social · 12/11/2025
Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research. 👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
010
Recursion @recursionpharma.bsky.social · 10/11/2025
At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx
000
Recursion @recursionpharma.bsky.social · 06/11/2025
Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...
020
Recursion @recursionpharma.bsky.social · 15/10/2025
Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."
031
Recursion @recursionpharma.bsky.social · 13/10/2025
🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪
020
Recursion @recursionpharma.bsky.social · 06/10/2025
Inside the AI transformation of drug discovery. On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com #GITEXGlobal #GITEX2025 #TechBio
020
Recursion @recursionpharma.bsky.social · 02/10/2025
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells. Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
121
Recursion @recursionpharma.bsky.social · 22/09/2025
We♥️our innovators. Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com. At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
111
Recursion @recursionpharma.bsky.social · 19/09/2025
Maintaining our sense of urgency, because patients are waiting. In a clip from the latest installment in our internal #RXU series – Chief R&D Officer and Chief Commercial Officer Najat Khan talks about the importance of urgency. #TechBio
010
Recursion @recursionpharma.bsky.social · 18/09/2025
A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...
011
Recursion @recursionpharma.bsky.social · 16/09/2025
“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones 👉 event.webcasts.com/viewer/event...
000
Recursion @recursionpharma.bsky.social · 15/09/2025
A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment. 👉 www.ft.com/content/9a8a...
000
Recursion @recursionpharma.bsky.social · 11/09/2025
🌄 The peak is now the basecamp. A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...
011
Recursion @recursionpharma.bsky.social · 05/09/2025
🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social), Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell 👉Read more: insights.citeline.com/in-vivo/lead...
010
Recursion @recursionpharma.bsky.social · 04/09/2025
📣 The inaugural episode of TechBio Talks is now live! Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare. ▪️ Spotify: open.spotify.com/show/2bjoBPs... ▪️ YouTube: youtube.com/playlist?lis...
000
Recursion @recursionpharma.bsky.social · 27/08/2025
🔹 Join us in September as Recursion executives present at two upcoming investor conferences: ▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference ▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference 👉 Learn more and tune in here: ir.recursion.com. #investor #IR #IRconference
000
Recursion @recursionpharma.bsky.social · 26/08/2025
🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now: ▪️ Spotify: open.spotify.com/show/2bjoBPs... ▪️ YouTube: www.youtube.com/playlist?lis...
021
Recursion @recursionpharma.bsky.social · 22/08/2025
🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.
000
Recursion @recursionpharma.bsky.social · 19/08/2025
An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...
021
Recursion @recursionpharma.bsky.social · 08/08/2025
💡 “It’s not a taller ladder, it’s an elevator.” In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio
010
Recursion @recursionpharma.bsky.social · 04/08/2025
Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...
012
Recursion @recursionpharma.bsky.social · 01/08/2025
🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio
011
Recursion @recursionpharma.bsky.social · 30/07/2025
At the AI x BIO Summit, hosted by Decoding Bio & NYSE, Recursion Chief R&D and Chief Commercial Officer Najat Khan spoke w/ @biotechtv.bsky.social about how we’re addressing the high failure rate in drug discovery using data and AI. 👉 full conversation here: biotechtv.com/post/recursi... #TechBio
020
Recursion @recursionpharma.bsky.social · 29/07/2025
Join our (L)earnings Call on Tuesday, August 5. Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST. 👉 Submit questions: forms.gle/ciFX2KbLfkAv... 👉 Read more: ir.recursion.com/news-release...
010
Recursion @recursionpharma.bsky.social · 25/07/2025
“How do we tap the potential in these data sets that can truly unlock better trials for patients, reduce timelines, and improve the patient experience?” - Sid Jain, SVP of clinical development and data science at Recursion, in a new article in Clinical Leader. www.clinicalleader.com/doc/clinical...
010
Recursion @recursionpharma.bsky.social · 24/07/2025
#ThrowbackThursday: Bold bets, breakthroughs & bottlenecks in #AI drug discovery at #BIO. In June, Recursion chief R&D & chief commercial officer Najat Khan, PhD joined industry leaders to discuss the tangible progress that’s already been made leveraging data & AI-led approaches in drug discovery.
012
Recursion @recursionpharma.bsky.social · 21/07/2025
✨Live from #ICML! Researchers from @valenceai.bsky.social – Recursion’s #AI research engine – had a great time sharing our #ML breakthroughs at ICML last week in posters & presentations. 👉 Keep up with all the latest research at Valence here: www.valencelabs.com
042
Recursion @recursionpharma.bsky.social · 18/07/2025
In an industry where over 90% of drug candidates fail, we are relentlessly working to find a better way. A new feature in @wired.com highlights the dedicated drug hunters at Recursion using #AI to find new ways to tackle complex diseases. www.wired.com/story/artifi... 🧪 #TechBio
031
Recursion @recursionpharma.bsky.social · 15/07/2025
🚀 How #TechBio is transforming drug discovery with data, AI and compute. Erik Douglas, VP of Product at Recursion, will present onstage at Ai4 happening Aug. 11-13 at the MGM Grand in Las Vegas. ai4.io/vegas/regist... #TechBio #AI #Ai4
010
Recursion @recursionpharma.bsky.social · 14/07/2025
Advancing full-stack #AI solutions. Sid Jain, SVP of Clinical Development & Data Science, discussed how Recursion is applying AI & technology to accelerate the discovery & development of new medicines in a webinar with Drug Discovery World. www.ddw-online.com/webinar-how-... #TechBio 🧪
010
Recursion @recursionpharma.bsky.social · 09/07/2025
Check out our latest ML advances at #ICML2025! 🔹 We’ll be presenting: 📎 Paper 1: Phenom-2 foundation model 📎 Paper 2: New framework to enhance transcriptomics by distilling knowledge from microscopy images 📎 Workshop: SIM: Scaling Up Interventional Models (sites.google.com/view/sim-icm...)
010
Recursion @recursionpharma.bsky.social · 07/07/2025
A new feature in @pharmaphorum.bsky.social gets behind the buzzwords to look at what’s needed – namely, data quality, team culture, and clinical execution – to truly shift to an AI-led approach to developing new #cancer drugs across the industry. 👉 pharmaphorum.com/deep-dive/bu... #TechBio 🧪
020
Recursion @recursionpharma.bsky.social · 30/06/2025
🤖 This week, we’re letting the robots take over while the humans recharge during our company-wide summer holiday. See you next week!⛱️ 🌞
030
Recursion @recursionpharma.bsky.social · 25/06/2025
Why Big Pharma is increasingly working with #TechBio partners. Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD, speaks with Peter Lawson, a biotech analyst at Barclays. 👉 Watch the full webcast here: barclays.webcasts.com/starthere.js...
010
Recursion @recursionpharma.bsky.social · 24/06/2025
We had a great turnout for #MoML 2025. Sponsored by Recursion & @valenceai.bsky.social, MoML convenes researchers from academia & industry to discuss how ML can address key scientific goals related to molecular modeling, molecular interactions & therapeutic design. 👉https://portal.ml4dd.com/ 🧪
020
Recursion @recursionpharma.bsky.social · 23/06/2025
2 weeks ago, Kelly Zalocusky, Senior Director of Computational Biology, joined a panel at London Tech Week to discuss “AI in Action.” On June 24, she'll present at Discovery & Development Europe on “Unlocking Drug Discovery At Scale Through Lab Automation & AI." oxfordglobal.com/discovery-de...
010
Recursion @recursionpharma.bsky.social · 20/06/2025
Recursion cofounder & CEO Chris Gibson sat down with David Bearss, cofounder & CEO of Halia Therapeutics & host of the Good Medicine Podcast, to discuss the original Recursion pitch, the rise of #TechBio, and why he believes a massive sea change is coming soon. 👉 www.youtube.com/watch?v=0LaO...
010
Recursion @recursionpharma.bsky.social · 18/06/2025
Recursion has joined the Council for Responsible Use of AI in Clinical Trials, launched today from Advarra, along with leaders from Sanofi and Velocity Clinical Research, Inc., to drive responsible AI innovation in clinical R&D. www.advarra.com/news/advarra... #clinicaltrials 🧪
030